Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218596 | 0.81 | KMT2A (0.48) | TRPV4KDM4EKMT2ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4387884 | 0.81 | KMT2A (0.48) | TRPV4KDM4EKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4382904 | 0.80 | LMNA (0.45) | KDM4EKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4385367 | 0.78 | HTT (0.51) | KDM4EKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4384916 | 0.78 | MAOB (0.46) | ALDH1A1TDP1LMNASMN1; SMN2 | |
| SCHEMBL4391011 | 0.77 | LMNA (0.54) | KMT2AALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL4379445 | 0.77 | LMNA (0.41) | KDM4EKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4379552 | 0.77 | LMNA (0.52) | KMT2AALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL13588947 | 0.77 | KMT2A (0.45) | TRPV4KDM4EKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4394032 | 0.77 | ALDH1A1 (0.52) | KDM4EKMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | TRPV4 13/4885KDM4E 560/4885KMT2A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.